drugset / Trial / NCT02206711

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

NCT02206711

Phase 1 Completed 21 enrolled ViiV Healthcare GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelOther

Summary

The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, safety and tolerability of a single oral dose of \[14C\] BMS-955176 in healthy male subjects. There is no formal research hypothesis to be statistically tested for this study.

Timeline

Start
2014-08-08
Primary completion
2014-09-09
Completion
2014-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-955176 Other / unclassified 180 mg Oral